Kings College London, School of Medicine, London, UK.
Mult Scler. 2010 Sep;16(9):1031-43. doi: 10.1177/1352458510368985. Epub 2010 Jun 15.
Fractures resulting from osteoporosis are a major cause of morbidity and mortality in the developed world. People with multiple sclerosis experience reduced mobility and are susceptible to falls. Glucocorticoid use and reduced mobility are known risk factors for osteoporosis. This paper is a review of osteoporosis in people with multiple sclerosis, looking at its prevalence, risk factors and possible mechanisms. We also review management guidelines for osteoporosis in the general population and use these to propose guidelines for osteoporosis management amongst multiple sclerosis patients. A number of studies have examined the incidence of reduced bone mineral density amongst people with multiple sclerosis; the majority provide convincing evidence that bone mineral density is significantly reduced in multiple sclerosis patients. The most significant risk factors appear to arise from the chronic disease process of multiple sclerosis and not from glucocorticoid use. There are currently no guidelines or consensus as how best to treat osteoporosis amongst multiple sclerosis patients despite their being at an increased risk. We propose an algorithm for the screening and treatment of osteoporosis in people with multiple sclerosis.
骨质疏松症导致的骨折是发达国家发病率和死亡率的主要原因。多发性硬化症患者活动能力下降,容易摔倒。糖皮质激素的使用和活动能力下降是骨质疏松症的已知危险因素。本文综述了多发性硬化症患者的骨质疏松症,探讨了其患病率、危险因素和可能的发病机制。我们还回顾了一般人群中骨质疏松症的管理指南,并利用这些指南为多发性硬化症患者的骨质疏松症管理提出建议。许多研究都调查了多发性硬化症患者骨密度降低的发生率;大多数研究都有充分证据表明多发性硬化症患者的骨密度明显降低。最显著的危险因素似乎来自多发性硬化症的慢性疾病过程,而不是糖皮质激素的使用。尽管多发性硬化症患者的风险增加,但目前尚无关于如何最好地治疗骨质疏松症的指南或共识。我们提出了一种多发性硬化症患者骨质疏松症筛查和治疗的算法。